Navigation Links
Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award

Unique probiotic strain, GanedenBC30, recognized for superior survivability and for opening new food and beverage product categories

CLEVELAND, Dec. 16 /PRNewswire/ -- Frost & Sullivan, the international growth consulting company, named Ganeden Biotech Inc. the recipient of its 2008 North American Food and Beverage Probiotics Product Innovation Award. The award recognizes Ganeden Biotech's innovative probiotic strain, GanedenBC30(TM), for opening new development initiatives in food and beverage product categories.

Frost & Sullivan's prestigious Probiotics Product Innovation award was granted to Ganeden Biotech for the advancement of the patented technology driving GanedenBC30. GanedenBC30 is able to survive harsh manufacturing processes, such as baking and freezing, as well as the acidic environment of the digestive tract better than other commercially available probiotic strains. This probiotic bacteria is more robust than traditional probiotic strains because it is protected by a spore, which is analogous to a seed and accounts for the strain's superior viability. The spore protects the cell's genetic material from the heat and pressure of manufacturing processes, challenges of shelf life and the acid and bile to which it is exposed to during digestive transit. The viable spore is then able to grow and multiply into new cells in the small and large intestines.

"The introduction of GanedenBC30 has certainly expanded the application of probiotics into product areas that were previously unavailable within food and beverage markets," said Dr. Deborah Cross, Industry Analyst at Frost & Sullivan. "The number of products available has already been enhanced substantially in previously undeveloped sectors such as bakery and snacks." GanedenBC30 has many times the rate of survival of the probiotic strains typically found in most probiotic-enhanced yogurts and can survive baking temperatures above 350 degrees Fahrenheit, making it particularly effective and robust.

In 2008, Ganeden Biotech teamed up with a number of food and beverage manufacturers to develop a wide variety of probiotics-enhanced products, including non-refrigerated nutrition bars, condensed soups, muffins and frozen yogurt. GanedenBC30 is also available in the over-the-counter probiotic products under the Digestive Advantage and Sustenex brands.

"We are grateful for Frost & Sullivan's recognition of our hard work in developing a powerful probiotic strain that can provide consumers with a range of health benefits," said Ganeden Biotech CEO Andrew Lefkowitz. "We look forward to continuing to work with food and beverage manufactures in developing innovative probiotic-enhanced products to help consumers lead happier and healthier lives."

About Ganeden Biotech

Founded in 1996, Ganeden Biotech Inc. is based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage(R) and Sustenex(TM) brands. It also licenses its patented probiotic bacteria, GanedenBC30(TM), for use in commercial food and beverage applications, medical foods, nutraceuticals and in animal health industries. GanedenBC30 is self-affirmed GRAS (Generally Recognized As Safe) by an independent panel of experts assembled to assess its safety in use as a food ingredient. For more information about licensing opportunities visit and for probiotic supplement information visit or

About Frost & Sullivan

Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

SOURCE Ganeden Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isabellas Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic
2. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
3. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
4. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
5. Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.
6. Axial Biotech Launches Genetic Test for Adolescent Idiopathic Scoliosis (AIS)
7. Investor Group Reconfigures Proposed Slate of Replacement Directors for Trinity Biotech
8. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
9. Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
10. Micromet Added to NASDAQ Biotechnology Index
11. Biotech Endorsement Insurance Discount Expanded to Nebraska, Kansas Growers Planting Corn with HERCULEX XTRA Traits
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... an additional independent director, and the Company welcomes ... allegations in a recent anonymous internet report on NW ... initiatives. Linda Powers stated, "We agree ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):